Search
Displaying results 561 to 570 of 596.
Helmholtz researches holistic solutions for pandemic response
To deal with the Corona pandemic and its effects, we need scientific knowledge and solutions that go far beyond health research. The pandemic has revealed the stress limits of our critical infrastructures and dependencies on global supply chains. Helmholtz scientists…
CRISPR discovery from Würzburg paves the way for novel COVID testing method
Most conventional molecular diagnostics usually detect only a single disease-related biomarker. Great examples are the PCR tests currently used to diagnose COVID-19 by detecting a specific sequence from SARS-CoV-2. Such so-called singleplex methods provide reliable…
How well are we protected six months after infection or vaccination?
How long and how well does the human immune system remember an encounter with SARS-CoV-2 or an encounter with at least fragments of the virus, as is the case with vaccination? One year? Two years? And during that time, how well is one still protected from infection with…
iCAIR® consortium delivers first results on the way to inhalable drugs against SARS-CoV-2
While the first vaccines against SARS-CoV-2 have now been approved in Europe and other countries, drugs for specific and efficient treatment of COVID-19 have as yet only limited availability – but are urgently needed. Because of the typical long drug development…
New viruses, new challenges
Viruses are small particles - about 1000x smaller than human cells - that exploit their host's metabolism to replicate. There are many thousands of viruses circulating in the animal world that could spread to humans. SARS-CoV-2 has shown how quickly new viruses can…
World Tuberculosis Day 2021: New drugs for old bugs
The department Microbial Natural Products at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a joint site of Helmholtz Centre for Infection Research (HZI) with Saarland University, is exploring soil bacteria for new active substances to solve these…
Putting pathogens on mute
Pseudomonas aeruginosa is capable of colonizing almost every part of the human body, making it the causative agent of a wide range of infectious diseases. The reason for the success of the bacterium lies, among other things, in its ability to produce and settle in…
Würzburg researchers track down resistance in CAR-T cell therapy
Multiple myeloma is a malignant cancer of the bone marrow. A great hope in the fight against the so far incurable disease rests on new immunotherapies, in particular on the treatment with CAR-T cells. T cells are white blood cells that serve the immune defense. In their…
HZI appoints Fabian Leendertz as founding director of the Helmholtz Institute for One Health
Fabian Leendertz was previously head of the research group “Epidemiology of Highly Pathogenic Microorganisms” at the Robert Koch Institute. As director of the HIOH, Leendertz will first dedicate himself to developing a research concept for the HIOH, which will be…
CoVerage analyses lineage dynamics of SARS-CoV-2 variants
CoVerage enables evaluation of epidemiological dynamics of different SARS-CoV-2 variants This is where the CoVerage web resource comes in. It can be used to identify particularly successful SARS-COV-2 lines and predict their further spread, taking epidemiological…
